Free Trial
NASDAQ:IONS

Ionis Pharmaceuticals (IONS) Stock Price, News & Analysis

Ionis Pharmaceuticals logo
$42.98 -0.61 (-1.40%)
Closing price 07/3/2025 02:44 PM Eastern
Extended Trading
$42.64 -0.34 (-0.79%)
As of 07/3/2025 04:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Ionis Pharmaceuticals Stock (NASDAQ:IONS)

Key Stats

Today's Range
$42.44
$43.66
50-Day Range
$29.74
$43.59
52-Week Range
$23.95
$52.34
Volume
1.34 million shs
Average Volume
1.60 million shs
Market Capitalization
$6.84 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$58.25
Consensus Rating
Moderate Buy

Company Overview

Ionis Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
94th Percentile Overall Score

IONS MarketRank™: 

Ionis Pharmaceuticals scored higher than 94% of companies evaluated by MarketBeat, and ranked 75th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Ionis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 13 buy ratings, 3 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Ionis Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Ionis Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Ionis Pharmaceuticals are expected to grow in the coming year, from ($3.50) to ($2.41) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Ionis Pharmaceuticals is -14.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Ionis Pharmaceuticals is -14.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Ionis Pharmaceuticals has a P/B Ratio of 11.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Ionis Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    9.16% of the float of Ionis Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Ionis Pharmaceuticals has a short interest ratio ("days to cover") of 8.4.
  • Change versus previous month

    Short interest in Ionis Pharmaceuticals has recently decreased by 4.11%, indicating that investor sentiment is improving.
  • Dividend Yield

    Ionis Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Ionis Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.16% of the float of Ionis Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Ionis Pharmaceuticals has a short interest ratio ("days to cover") of 8.4.
  • Change versus previous month

    Short interest in Ionis Pharmaceuticals has recently decreased by 4.11%, indicating that investor sentiment is improving.
  • News Sentiment

    Ionis Pharmaceuticals has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Ionis Pharmaceuticals this week, compared to 8 articles on an average week.
  • Search Interest

    19 people have searched for IONS on MarketBeat in the last 30 days. This is an increase of 90% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Ionis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Ionis Pharmaceuticals insiders have bought 2,377.19% more of their company's stock than they have sold. Specifically, they have bought $477,900.00 in company stock and sold $19,292.00 in company stock.

  • Percentage Held by Insiders

    Only 2.60% of the stock of Ionis Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    93.86% of the stock of Ionis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Ionis Pharmaceuticals' insider trading history.
Receive IONS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IONS Stock News Headlines

Banks aren’t ready for this altcoin—are you?
The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket change.
Barclays Upgrades Ionis Pharmaceuticals (IONS)
Ionis Pharmaceuticals (NASDAQ:IONS) Upgraded at Barclays
See More Headlines

IONS Stock Analysis - Frequently Asked Questions

Ionis Pharmaceuticals' stock was trading at $34.96 at the beginning of the year. Since then, IONS shares have increased by 22.9% and is now trading at $42.98.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) posted its quarterly earnings data on Wednesday, April, 30th. The company reported ($0.93) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.14. The firm's revenue was up 10.9% compared to the same quarter last year.
Read the conference call transcript
.

Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ionis Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
4/30/2025
Today
7/05/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:IONS
Employees
1,069
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$58.25
High Stock Price Target
$77.00
Low Stock Price Target
$37.00
Potential Upside/Downside
+35.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
18 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$453.90 million
Pretax Margin
-64.65%

Debt

Sales & Book Value

Annual Sales
$705 million
Price / Cash Flow
N/A
Book Value
$3.73 per share
Price / Book
11.52

Miscellaneous

Free Float
155,021,000
Market Cap
$6.84 billion
Optionable
Optionable
Beta
0.23

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:IONS) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners